MONOCLONAL ANTIBODY FOR TROPHOBLASTIC DISEASE DIAGNOSIS

Project: Research project

Description

This study wil utilize newly developed monoclonal antibodies against free
beta hCG and intact hCG to determine if malignant sequelae of hydatidiform
mole can be predicted at initial diagnosis. Patients from the Southern Trophoblastic Disease Center will be studied.
Radioimmunoassays for free beta hCG and intact hCG will be performed at the
time of diagnosis to determine whether the ratio of free beta hCG to total
hCG may be of value in predicting which molar pregnancies will develop
persistent disease. Then serial serum and urinary assays will be performed
in order to characterize the regression curve of free beta hCG. This will
establish the time period available to demonstrate free beta hCG as an
indicator of persistent trophoblastic disease. Immunohistochemical studies
utilizing the free beta and intact hCG monoclonal antibodies will be
performed on the initial molar tissue to define the site of secretion and
to correlate this with histologic appearance of the mole. If the study is successful in predicting the 20% of patients who will
develop persistent trophoblastic disease, prophylactic chemotherapy could
be given leading to a significant reduction in malignant sequelae and a
substantial savings in money and morbidity for patients with molar
pregnancy. (3)
StatusFinished
Effective start/end date9/1/858/31/88

Funding

  • National Institutes of Health
  • National Institutes of Health
  • National Institutes of Health

Fingerprint

Monoclonal Antibodies
Hydatidiform Mole
Radioimmunoassay
Morbidity
Drug Therapy
Serum

ASJC

  • Medicine(all)